AnPac Bio-Medical Science Co. Ltd. (ANPC) shares surged 28.4% to trade at $6.42 in after-market on Friday, April 16, 2021. ANPC’s stock lost -10.71% to close Friday’s normal trading session at $5.00. ANPC shares have fallen by -39.17% over the last 12 months, and they have moved down by -13.34% in the past week. Over the past three months, the stock has lost -12.43%, while over the past six months, it has added 42.05%.
AnPac Bio setting new record sale for its flagship products in Q1
On April 16, 2021, AnPac Bio-Medical Science CoLtdsaid that it has observed strong demand for its flagship product line and paid CDA cancer tests in Q1. ANPC stock is expecting approximately a 130% increase over the same period last year. For ANPC stock, immunology tests and annual physical checkups paid CDA-based tests had the highest test volume among all these tests in Q1, 2021.
New CDA Pro Sensor
On March 09, 2021, AnPac Bio-Medical Science Co., Ltd said that it completed evaluations of a new generation multi-cancer detection sensor CDA Pro Sensor (CDAPS).CDAPS has many advantages over the last generation such as detection signal stability, sensor device yield, sensor cost, and detection sensitivity and specificity. Also, the new sensor cost has been reduced up to 137%
Regaining Nasdaq compliance
On March 6, 2021, AnPac Bio-Medical Science announced that they received a letter from Nasdaq on March 4, confirming that ANPC stock has regained compliance with Nasdaq Listing Rule 5450(b)(2)(A)”) and the matter has now been closed by Nasdaq.
On October 9, 2020, Nasdaq informed ANPC stock about its listed rule and provide ANPC stock with an extension of 180 days to regain the listing requirement.
US patent for Cancer Differentiation Analysis (CDA)
On February 16, 2021, AnPac Bio-Medical Science announced that its Cancer Differentiation Analysis (CDA) technology was granted a US patent for multi-cancer detection.
Previously, On December 14, 2020, ANPC stock declared significant progress in detecting pre-cancer diseases by its sensor technologies.
The record sales announcement about its product line was the reason behind its surging on Friday. We can expect ANPC stock will continue its momentum at the start of the new week.
About ANPC stock
AnPac Bio is a biotechnology company founded in 2010 and its headquarter is in China. ANPC stock issued 128 patents as of June 30, 2020, and is focused on early cancer screening and detection. AnPachas two certified clinical laboratories in China and one CLIA and CAP-accredited clinical laboratory and one CLIA registered clinical laboratory in the United States.